VEGFA and neoplasm: Noteworthily, siRNA against VEGF (3.5 nmol, siRNA/MSN: 1/40 w/w) was also systematically administrated into orthotropic ovarian tumor-bearing mice with MSNs as carriers, showing significant inhibition of angiogenesis and retardation of tumor growth [68].